T529-15D3-2E5-4G12-1A7 [1A7, CTCC 10753] (ATCC® HB-10501)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: killing cancer cells.

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease killing cancer cells.
Applications
The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein.
The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells.
These bispecific antibodies are useful in killing cancer cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein
Cellular Products
immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein
Comments
The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines.
The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein.
The murine hybridoma 3G8 recognizes the human Fc gamma receptor III.
The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein.
The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells.
These bispecific antibodies are useful in killing cancer cells.
Complete Growth Medium Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10%
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor Chiron Corp.
References

Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000